Labcorp Holdings (LH) is back in focus after reporting second quarter revenue of US$3,731.1 million and net income of US$298.7 million. The company also raised full year 2026 guidance and highlighted new precision oncology and consumer genetic testing offerings.

Against this backdrop of new oncology and genetic testing launches, Labcorp Holdings’ share price has gained 8.84% over the past month and 21.56% over the past 90 days, while the 1 year total shareholder return sits at 19.80%. This suggests momentum has been building around the stock’s earnings delivery and raised 2026 outlook.

If Labcorp’s recent precision medicine updates have caught your attention, it could be a useful moment to look across the sector and see how other healthcare focused AI opportunities compare through the 41 healthcare AI stocks

The recent jump in Labcorp Holdings could be read as a vote of confidence in its precision testing push, or as investors simply crowding into a popular healthcare AI story. The next step is to see what the valuation implies.

Most Popular Narrative: 4.4% Undervalued

Labcorp Holdings closed at $312.34 compared with a widely followed fair value estimate of about $326.81, which frames how some investors are thinking about the recent price strength.

The introduction of innovative tests in oncology, women's health, autoimmune disease, and neurology is anticipated to capture more test volume and outpace growth in the broader market, positively impacting revenue and earnings. The use of AI and technology innovations is enhancing operational efficiencies, improving margins through platforms like eClaim Assist and Labcorp Diagnostic Assistant.

Curious what kind of revenue mix, margin uplift and earnings path need to line up for that fair value to make sense. The narrative walks through a detailed growth runway, a future profit profile and the valuation multiple it assumes the market will accept.

Result: Fair Value of $326.81 (UNDERVALUED)

However, the story of Labcorp Holdings still carries real risks, including potential revenue pressure from PAMA-related Medicare changes and tougher pricing or contract renewals in diagnostics.

Next Steps

With mixed sentiment around Labcorp Holdings, it makes sense to quickly review the full picture, including both concerns and potential upsides through the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Labcorp Holdings?

If Labcorp has sharpened your interest, do not stop here. The screener can surface fresh ideas that match your style before the rest of the market reacts.

• Target reliable income by reviewing companies in the 7 dividend fortresses that focus on higher yields supported by current financials.
• Hunt for value opportunities by checking the screener containing 18 high quality undiscovered gems that may sit off most investors’ radar but still show solid fundamentals.
• Prioritise capital preservation and steadier compounding with the 82 resilient stocks with low risk scores that filters for stocks with lower assessed risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.